The U.S. Food and Drug Administration is holding a committee meeting next month to reconsider restrictions on several peptide products. Multiple reports say FDA scientists and career researchers have raised concerns in internal documents about the available evidence for the peptides being considered, citing limited data on both efficacy and safety. NPR and NBC News report that some peptides have not been studied in humans, and that reviewers flag a lack of good evidence supporting their use.
Several outlets also describe a debate over the composition of the panel and the influence of proponents linked to Robert F. Kennedy Jr., who has advocated for greater access to peptides. PBS NewsHour, The Washington Times, and The Independent report that the panel will include experts described as promoting or connected to the peptide industry, and that some participants have financial ties to that field.
Ars Technica and MedPage Today similarly report that FDA career scientists oppose expanding access as they believe there is inadequate evidence to support the specific peptides under consideration, including those for production by compounding. The FDA posts meeting materials online, and the panel’s outcome is expected to inform whether access rules are eased.
